PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Tislelizumab and sitravatinib as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence following surgical resection: A multi-center, non-randomized, open-label phase 2 ...

Deep Learning Model for Natural Language to Assess Effectiveness of Patients With Non–Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guérin Therapy ...

Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered ...

4130Background: Growing evidence supports the prognostic and predictive value of circulating tumor DNA (ctDNA) detection in gastrointestinal cancers. Building on previous work that demonstrated the ...

The Working Group agreed on a recommended list of preanalytical minimum technical data elements, clinical context data elements, and patient context data elements for cfDNA-based CSF liquid biopsy in ...

CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase 3 study.

Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.

*N=29 for response outcomes. AE, adverse event; CI, confidence interval. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component ...

Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.

We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) ...

Chemotherapy plus anti-PD-1 or anti-PD-L1 in advanced PD-L1–negative squamous cell lung carcinoma: A systematic review and meta-analysis.